INmune Bio terminates $75M ATM sales agreement with RBC and BTIG effective Dec 19, 2025

Inmune Bio, Inc.

Company notified RBC and BTIG of termination on Dec 5 and Dec 9, 2025; effective Dec 19.
No termination penalties or expenses incurred.
Prior to termination, co. raised ~$10.5M net proceeds through sale of 1,353,469 shares.
Original agreement allowed up to $75M in at-the-market offerings since Aug 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.